The State Administration of Market Supervision recently issued the announcement of China’s National Standard No. 2 in 2022, among which the standard of technical specification for evaluation of new varieties of traditional Chinese medicine (plant medicine) (GB / T 412772022) will be officially implemented on October 1, 2022. The standard defines the terms and definitions of the evaluation of new varieties of traditional Chinese medicine (plant medicine), and stipulates the evaluation contents and basis, variety test, evaluation requirements, evaluation rules and records.
The standardization of traditional Chinese medicine is an important technical support for the development of traditional Chinese medicine. It is of great significance for promoting the academic development of traditional Chinese medicine, improving the clinical efficacy of traditional Chinese medicine, standardizing industry management, promoting the modernization of traditional Chinese medicine and accelerating the development of traditional Chinese medicine to the world. Recently, the WHO official website released the “who expert evaluation meeting on the treatment of covid-19 pneumonia with traditional Chinese medicine”. The report pointed out that traditional Chinese medicine can effectively treat covid-19 pneumonia, reduce the conversion of mild and common cases to severe cases, shorten the virus clearance time, and improve the clinical prognosis of mild and common patients. The report also encourages Member States to consider the integrated medical model (Integrated Traditional Chinese and Western medicine model) formed and applied in China. The agency pointed out that the role of traditional Chinese medicine in the treatment of covid-19 pneumonia was recognized by the WHO expert meeting, which is conducive to the international development of traditional Chinese medicine.
According to the theme database of financial Associated Press, among the relevant listed companies:
Guizhou Xinbang Pharmaceutical Co.Ltd(002390) has standardized planting bases for traditional Chinese medicine, and the holding subsidiary Guizhou Tongde Pharmaceutical Co., Ltd. has built or jointly built 100 genuine medicine bases in 21 provinces and cities including Guizhou, Guangxi, Yunnan and Xinjiang.
It is used in various traditional Chinese medicine products such as Yupei capsule and Shangdu Rehmannia capsule for the treatment of respiratory tract infection, including Yupei Rehmannia capsule.
